You are now leaving sigma-tau.fr
OUR MISSION: INNOVATE FOR THE SAKE OF HUMAN HEALTH
SIGMA-TAU was founded in 1957. It has become one of the main Italian pharmaceutical group with a worldwide presence, by combining research, successful products, industrial growth and ethics.
The mission of the group SIGMA-TAU is to improve the quality of life and human health. In order to honour this commitment and offer top-quality medicines, we invest heavily in:
•the continuous renewal of the technologic aspects of our production systems.
Research: the driving force in our development
Research, the main source of our efforts for innovation, enjoys continuous support from the company, as evidenced by the 10% share of our turnover dedicated to research. Our most recent areas of research include:
•the chemical and pharmacobiological study of carnitine and its derivatives, which are substances of natural origin particularly used to correct metabolic disorders in numerous pathologies,
•the development of new therapies in our traditional areas of expertise: cardiovascular, metabolic, gastrointestinal and central nervous system diseases,
•the development of innovative therapeutic solutions in oncology and autoimmune diseases.
In developing synthetic molecules and biotechnology medications, we are pursuing a dual objective: therapeutic efficacy and optimal tolerability.
Quality: an ethical value
Every day the SIGMA-TAU group puts great emphasis on quality.
This methodological approach enables the company to develop medicines of very high quality
As early as the 1980’s Dr. Claudio Cavazza, Founder of the SIGMA-TAU group, decided to give the company an international dimension, offering innovative solutions in key therapeutic fields: Cardiology, Gastroenterology, Infectiology, Neurology, Oncology, Osteoporosis, Pneumology, Rheumatology, Urology.
•12 subsidiaries worldwide: USA, Germany, Belgium, Spain, France, Netherlands, Portugal, United Kingdom, Switzerland and India, together with an international network of distribution under licence,
•2391 staff members around the world,
•Consolidated turnover of 663 million euros (2011),
•Share of investment in research: 10% of turnover.